Abstract
Atherosclerosis is still the basic cause of metabolic diseases, namely the adnormal lipid metabolism and cholesterol accumulation. As more and more in-depth clinical investigations are being conducted, modulation the high-density lipoprotein (HDL) pathway, particularly the ApoA1, has been particularly attracted attention. Until now, to use these biotechnological functions properly and in management of individuals still poses a challenge. This essay will range from the introduction and discussion on the working and significance of both ApoA1 mimetics and genetically engineered ApoA1, focusing majorly on their functions which involve in enhancing cholesterol efflux and providing anti-inflammatory benefits. Consequently, they as a whole play a role in improving cardiovascular health. The results suggest that novel therapies could just be the epiphany for atherosclerosis cure or reversal. The study delineates the emphasis on protein-based treatments as a move for the future in the management of cardiovascular diseases, which serves as the architecture of subsequent research. However, as time goes on, matching treatment by patients’ genetic and environmental considerations stays to be a roadblock. Next research is set to target unsuitable combinations and those effective and possible in different groups for the development of such strategies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
